Group 1 - The Shanghai Composite Index is at 4107.01 points, above the six-month moving average, with a decline of 0.46% [1] - The total trading volume of A-shares today is 1,429.956 billion yuan [1] - A total of 98 A-shares have surpassed the six-month moving average, with notable stocks including Xinweiling, Shenyu Co., and Wenkex Co., showing significant deviation rates of 7.90%, 7.78%, and 7.77% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the six-month moving average are: - Xinweiling (12.46% increase, 10.41% turnover rate, latest price 29.97 yuan, deviation rate 7.90%) [1] - Shenyu Co. (8.73% increase, 12.74% turnover rate, latest price 41.98 yuan, deviation rate 7.78%) [1] - Wenkex Co. (10.09% increase, 3.41% turnover rate, latest price 4.80 yuan, deviation rate 7.77%) [1] Group 3 - Other notable stocks with significant increases and their respective deviation rates include: - Tongce Medical (8.32% increase, 7.01% turnover rate, latest price 47.01 yuan, deviation rate 7.22%) [1] - Dibei Electric (10.01% increase, 6.78% turnover rate, latest price 20.88 yuan, deviation rate 7.10%) [1] - Guangming Real Estate (10.09% increase, 1.66% turnover rate, latest price 3.82 yuan, deviation rate 6.06%) [1]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a slight increase in stock price and mixed capital flow on January 13, 2026 [1] - As of January 13, 2026, Tongce Medical's stock closed at 42.48 yuan, with a trading volume of 15.21 million shares and a total transaction value of 653 million yuan [1] - The capital flow data shows a net outflow of 12.39 million yuan from institutional investors, while retail investors experienced a net outflow of 4.51 million yuan, indicating varied investor sentiment [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, reflecting a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 saw a single-quarter main revenue of 842 million yuan, with a net profit of 192 million yuan, both showing year-on-year increases of 2.34% and 2.31% respectively [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, alongside a gross profit margin of 41.69% [2] Group 3 - In the last 90 days, seven institutions have provided ratings for Tongce Medical, with four buy ratings and three hold ratings, and the average target price set at 5.29 billion yuan [2]

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - The core viewpoint of the article is that Tongce Medical has disclosed information regarding its total number of shareholders, which exceeds 90,000 as of January 10, 2026 [2] - The company emphasizes the importance of ensuring that all investors have fair access to information, indicating that future updates on shareholder numbers will be provided in formal periodic reports [2]

Core Viewpoint - Tongce Medical (600763) shows a steady growth in revenue and net profit, indicating a stable performance in the medical services sector [2]. Group 1: Stock Performance - As of January 12, 2026, Tongce Medical's stock closed at 42.34 yuan, up by 1.61%, with a turnover rate of 2.38% and a trading volume of 106,300 lots, resulting in a transaction value of 448 million yuan [1]. - On January 12, the net inflow of main funds was 22.82 million yuan, accounting for 5.09% of the total transaction value, while retail investors saw a net outflow of 21.28 million yuan, representing 4.75% of the total transaction value [1]. Group 2: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year, and a net profit attributable to shareholders of 514 million yuan, up by 3.16% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, which is a 2.31% increase year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2]. Group 3: Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 5.29 billion yuan [2].

来源：市场资讯 有投资者在互动平台向通策医疗提问："请问截止2026年1月10日公司的股东数是多少？" 针对上述提问，通策医疗回应称："您好，截至2026年1月10日公司股东总数为9万多。为确保所有投资 者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期报告为准，感谢您的关注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

证券之星消息，截至2026年1月7日收盘，通策医疗(600763)报收于41.02元，下跌0.65%，换手率 1.34%，成交量5.99万手，成交额2.46亿元。 1月7日的资金流向数据方面，主力资金净流出2848.85万元，占总成交额11.56%，游资资金净流入 914.14万元，占总成交额3.71%，散户资金净流入1934.71万元，占总成交额7.85%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance in its recent quarterly results [1][2] - As of January 6, 2026, Tongce Medical's stock closed at 41.29 yuan, with a trading volume of 79,900 hands and a total transaction amount of 329 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 9.82 million yuan, while retail investors saw a net inflow of 10.79 million yuan, indicating a mixed sentiment among different investor groups [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter results showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月5日收盘，通策医疗(600763)报收于41.14元，上涨2.31%，换手率 1.75%，成交量7.81万手，成交额3.19亿元。 1月5日的资金流向数据方面，主力资金净流出3346.42万元，占总成交额10.49%，游资资金净流入 1248.28万元，占总成交额3.91%，散户资金净流入2098.15万元，占总成交额6.58%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-05 | 41.14 | 2.31% | -3346.42万 | -10.49% | 1248.28万 | 3.91% | 2098.15万 | - 6.58% | | 2025-12-31 | 40.21 | -0.30% | -630.53万 | -3.86% | 285.32万 | 1.75% | 345.21万 | 2.11% | | ...

Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]